FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 319 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Νέος βιοδείκτης για τις γυναίκες πριν την εμμηνόπαυση August 1, 2019 FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative... February 27, 2025 Mom Diagnosed With Breast Cancer Adopts Healthy Lifestyle To Reinvent Her... November 7, 2021 Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast... February 9, 2023 Load more HOT NEWS Working Mom with Stage II Breast Cancer Receives Custom Wig Made... ESMO Call for Cancer Care Safeguards Reflected in the EU’s Health... Mobile Care Center Brings Breast Cancer Treatment to Amish and Mennonite... Cervical screening in Wales extended to every 5 years: Why the...
